English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

99m Tc-PSMA I&amp;S is a prostate-specific membrane antigen (PSMA) tracer that can be used for planar and SPECT/CT γ-imaging and radioguided surgery. The primary aim of this study was to estimate the dosimetry of 99m Tc-PSMA I&amp;S using a hybrid method (sequential γ-planar imaging and 1 single SPECT/CT) in healthy volunteers. The secondary aim was to depict the tracer biodistribution and tumor-to-background ratios (TBRs) in patients with prostate cancer (PCa). Methods: Dosimetry of 99m Tc-PSMA I&amp;S was investigated in 4 healthy volunteers. Whole-body planar imaging was acquired at 1, 2, 3, 6, and 24 h and SPECT/CT at 6 h after tracer injection. Contours of organs were drawn on all acquisitions to determine organ activity at each time point. Absorbed dose was estimated using 2 methods: independent curve-fitting manual method (Levenberg-Marquardt-based algorithm using dose factors from RAdiation Dose Assessment Resource [RADAR] website) and OLINDA/EXM software (version 2.0; HERMES Medical Solutions). Biodistribution of 99m Tc-PSMA I&amp;S was assessed in 10 patients with PCa on SPECT/CT images at 6 h. Tumor uptake (SUV max ), and TBR (tumor SUV max /background organ SUV mean ) using muscle (T/M), bladder (T/B), and intestine (T/I) as background organs were determined. Results: The mean injected activity of 99m Tc-PSMA I&amp;S was 717 MBq (range: 562-828 MBq). No adverse events related to the injection of 99m Tc-PSMA I&amp;S were reported. The average radiation effective dose was 0.0055 mSv/MBq with the RADAR manual method and 0.0052 mSv/MBq with OLINDA/EXM. Total body effective dose ranged between 3.33-4.42 and 3.11-4.23 mSv, respectively. All PCa patients showed high tracer uptake in primary and metastatic lesions with T/M, T/B, and T/I ranging from 5.29-110, 0.11-7.02, and 0.96-16.30, respectively. Conclusion: Effective doses of 99m Tc-PSMA I&amp;S were comparable to those known for most of the 99m Tc tracers and was lower than for the 68 Ga-labeled and 18 F-labeled agents. 99m Tc-PSMA I&amp;S SPECT/CT showed high TBR in PCa patients. This study can provide required data for translation and approval of 99m Tc-PSMA I&amp;S by regulatory agencies.

Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study

Radiation Dosimetry of ^99mTc-PSMA I&S: A Single-Center Prospective Study